PathoQuest provides iDTECT®, a GMP‑validated next‑generation sequencing platform that replaces traditional animal‑based biosafety assays with a fully digital, animal‑free workflow for viral safety screening and genetic characterization. The service, offered as a contract research organization from sites in France and the United States, delivers rapid, high‑sensitivity results and regulatory‑ready reports for biopharmaceutical developers needing adventitious virus detection and stability testing.
Funding
$17.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
6OSCFounders
Product
Problem
Biopharmaceutical developers must perform extensive viral safety and genetic stability testing to meet regulatory requirements, a process that often relies on time‑consuming, animal‑based assays and fragmented laboratory workflows, delaying development timelines and increasing costs.
Solution
PathoQuest offers iDTECT®, a GMP‑validated next‑generation sequencing (NGS) platform that replaces traditional biosafety assays with a fully digital, animal‑free workflow. The platform delivers high‑sensitivity viral adventitious agent screening across cell banks, process intermediates, and bulk drug substances, as well as detailed genetic characterization for clone selection and stability monitoring. By leveraging NGS, iDTECT provides rapid turnaround, quantitative results, and comprehensive data that are directly compatible with regulatory submissions. PathoQuest operates as a contract research organization, delivering both GMP and non‑GMP testing services from facilities in France and the United States, enabling biopharma companies to accelerate development while maintaining compliance.
Target Audience
Primary customers are biopharmaceutical companies and emerging biotech firms developing viral vectors, cell therapies, or protein biologics that require viral safety screening and genetic stability testing to meet regulatory approval.
Features
- GMP‑validated NGS assays for adventitious virus detection from cell lines to final drug product
- High‑resolution genetic characterization for clone selection, cell line stability, and product consistency
- Fully animal‑free testing workflow that reduces ethical concerns and assay variability
- Rapid data generation and analysis pipeline delivering results faster than conventional methods
- End‑to‑end CRO support, including sample handling, sequencing, bioinformatics, and regulatory‑ready reporting
- Dual‑site service model (France and U.S.) providing global coverage and compliance with regional GMP standards